Yihan Li
Barclays Financial institution PLC, Analysis Division
Hey, good afternoon, everybody. I am Yihan Li, Barclays European Biopharma Fairness Analysis Analyst. At present, it’s my pleasure to host Zealand Pharma, hearth chat with Adam Steensberg, the CEO of Zealand. So thanks for becoming a member of us at this time, and we’re delighted to have you ever right here to stroll us by way of your story. So truly, to begin with, I’ll hand it over to you, Adam, to have a short introduction of Zealand and do some shows.
Adam Steensberg
President & CEO
Completely. A pleasure to be right here. So Zealand Pharma, we’re right here to handle what we imagine is the most important well being care problem of our time, and that is the weight problems pandemic and all of the ailments that follows the weight problems pandemic, you may truly ascribe greater than 220 ailments to the rise in weight problems that we see these years, and we have to do one thing about this as a society.
So reworking the way forward for metabolic well being, that’s what Zealand is about. I will likely be making forward-looking statements at this time, as you in all probability count on. So if you consider our key priorities, then it is to redefine the near-term way forward for weight administration, actually centered on our 2 main property, petrelintide, which we’ve in partnership with Roche after which survodutide, which has been partnered out to Boehringer Ingelheim.
So these are the two main packages the place we, in fact, spend numerous efforts and in addition there will likely be great concentrate on this 12 months. However equally vital for us can be to construct the pipeline that follows these 2